Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00509600 | Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT01222195 | Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets |
| terminated |
| Phase 3 |
| 4 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Aug 2, 2012 |
| clinicaltrials |
| NCT00443300 | Effectiveness of Protected Environment Rooms for AML and MDS | terminated | — | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00081887 | Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia | terminated | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00513305 | Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia | terminated | Phase 3 | 67 | CephalonINDUSTRY | 2 | Aug 1, 2012 | clinicaltrials |
| NCT00514189 | Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines | terminated | Phase 1 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2012 | clinicaltrials |
| NCT00127881 | Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | terminated | Phase 3 | 76 | Emergent Product Development Seattle LLCINDUSTRY | 5 | Jul 26, 2012 | clinicaltrials |
| NCT01029509 | Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes | terminated | Phase 1 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 23, 2012 | clinicaltrials |
| NCT00893997 | PR1 Vaccination in Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2012 | clinicaltrials |
| NCT00151736 | Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 88 | CephalonINDUSTRY | 5 | Jun 11, 2012 | clinicaltrials |
| NCT00253552 | G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders | terminated | N/A | 4 | OHSU Knight Cancer InstituteOTHER | 1 | May 28, 2012 | clinicaltrials |
| NCT00499889 | Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients | terminated | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2012 | clinicaltrials |
| NCT00827099 | Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer | terminated | Phase 2 | 5 | Northside Hospital, Inc.OTHER | 1 | Mar 23, 2012 | clinicaltrials |
| NCT01066468 | Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 13, 2012 | clinicaltrials |
| NCT00074750 | Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) | terminated | Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 22, 2012 | clinicaltrials |
| NCT00124748 | Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)(TOPS) | terminated | Phase 3 | 476 | Novartis PharmaceuticalsINDUSTRY | 6 | Feb 3, 2012 | clinicaltrials |
| NCT00419081 | Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens | terminated | Phase 2 | 100 | BioCryst PharmaceuticalsINDUSTRY | 1 | Jan 23, 2012 | clinicaltrials |
| NCT00446303 | A Phase II Study of Maintenance With Azacitidine in MDS Patients | terminated | Phase 2 | 39 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Jan 19, 2012 | clinicaltrials |
| NCT00473551 | Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2011 | clinicaltrials |
| NCT00895297 | Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia(Dasatinib) | terminated | Phase 2 | 50 | European Society for Blood and Marrow TransplantationNETWORK | 4 | Dec 7, 2011 | clinicaltrials |
| NCT01127542 | RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial(RESPeCT) | terminated | Phase 2 | 1 | The Christie NHS Foundation TrustOTHER | 1 | Dec 5, 2011 | clinicaltrials |
| NCT00519090 | Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)(ENEST) | terminated | Phase 3 | 6 | Novartis PharmaceuticalsINDUSTRY | 10 | Nov 7, 2011 | clinicaltrials |
| NCT00918931 | Obatoclax for Systemic Mastocytosis | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 4, 2011 | clinicaltrials |
| NCT00428077 | Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | terminated | Phase 2 | 4 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 2, 2011 | clinicaltrials |
| NCT00430443 | Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML | terminated | Phase 1 | 3 | Callisto PharmaceuticalsINDUSTRY | 1 | Aug 31, 2011 | clinicaltrials |
| NCT00915811 | Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin(FB-ATG) | terminated | Phase 2 | 20 | King's College Hospital NHS TrustOTHER | 1 | Aug 17, 2011 | clinicaltrials |
| NCT00839059 | Lenalidomide In Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 14 | University of UlmOTHER | 1 | Jul 29, 2011 | clinicaltrials |
| NCT00002778 | Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia | terminated | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00003561 | Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | terminated | Phase 2 | 48 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00524667 | HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia | terminated | Phase 2 | 6 | CancerCare ManitobaOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT01125787 | Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab | terminated | Phase 2 | 1 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00768339 | A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas | terminated | Phase 1 / Phase 2 | 25 | Aegera TherapeuticsINDUSTRY | 2 | Jul 13, 2011 | clinicaltrials |
| NCT01018069 | AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen | terminated | Phase 2 | 60 | Aegera TherapeuticsINDUSTRY | 3 | Jul 13, 2011 | clinicaltrials |
| NCT00112619 | Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors | terminated | Phase 1 | 19 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jun 30, 2011 | clinicaltrials |
| NCT00531310 | Reduced Intensity AlloSCT in(CML) With Persistent Disease(CML) | terminated | Phase 2 | 5 | Columbia UniversityOTHER | 1 | Apr 14, 2011 | clinicaltrials |
| NCT00187005 | Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | terminated | Phase 3 | 53 | St. Jude Children's Research HospitalOTHER | 1 | Mar 30, 2011 | clinicaltrials |
| NCT00813501 | Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases | terminated | — | 60 | City of Hope Medical CenterOTHER | 1 | Mar 7, 2011 | clinicaltrials |
| NCT01034410 | A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 2 | 90 | Antisoma ResearchINDUSTRY | 4 | Feb 2, 2011 | clinicaltrials |
| NCT00486265 | Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML) | terminated | Phase 1 | 47 | AstraZenecaINDUSTRY | 2 | Dec 21, 2010 | clinicaltrials |
| NCT00631059 | Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients | terminated | N/A | 40 | University of California, IrvineOTHER | 1 | Oct 13, 2010 | clinicaltrials |
| NCT00279773 | Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia | terminated | Phase 1 | 34 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 30, 2010 | clinicaltrials |
| NCT00646165 | Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia | terminated | Phase 1 | 1 | Mundipharma Research LimitedINDUSTRY | 1 | Mar 31, 2010 | clinicaltrials |
| NCT00319930 | Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL | terminated | Phase 1 | 10 | BiogenINDUSTRY | 1 | Mar 8, 2010 | clinicaltrials |
| NCT00322673 | Study of XL999 in Patients With Acute Myeloid Leukemia (AML) | terminated | Phase 2 | 14 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT00004058 | 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder | terminated | Phase 1 | — | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jan 26, 2010 | clinicaltrials |
| NCT00362466 | A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy | terminated | Phase 3 | 3 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 20, 2009 | clinicaltrials |
| NCT00306332 | T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation | terminated | Phase 3 | 250 | Radboud University Medical CenterOTHER | 1 | Aug 18, 2009 | clinicaltrials |
| NCT00344786 | Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL | terminated | Phase 1 | 15 | BiogenINDUSTRY | 1 | Jun 5, 2009 | clinicaltrials |
| NCT00543972 | Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia | terminated | Phase 1 | 12 | SanofiINDUSTRY | 3 | May 14, 2009 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2012source: clinicaltrials